Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Proia

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
Hormones & Cancer|February 10, 2016
Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast CancerAbena S Agyeman, Wesley J Jun, David A Proia, et al.
Targeted Oncology|August 1, 2014
The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancerDonald L Smith, Jaime Acquaviva, Manuel Sequeira, et al.
Molecular Cancer Therapeutics|September 27, 2012
Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespibJaime Acquaviva, Donald L Smith, Jim Sang, et al.
Molecular Cancer Therapeutics|January 9, 2014
Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespibJaime Acquaviva, Donald L Smith, John-Paul Jimenez, et al.
Oncotarget|September 10, 2016
STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcomaChristine M Heske, Arnulfo Mendoza, Leah D Edessa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2016
Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with ChemoradiationYifan Wang, Hui Liu, Lixia Diao, et al.
Plos One|December 5, 2014
Inhibiting heat shock protein 90 (HSP90) limits the formation of liver cysts induced by conditional deletion of Pkd1 in miceZachary B Smithline, Anna S Nikonova, Harvey H Hensley, et al.
Oncotarget|October 26, 2016
Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer modelsEgor Bobrov, Natalia Skobeleva, Diana Restifo, et al.
Cancers|May 27, 2015
The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma CellsRoberto Gomez-Casal, Chitralekha Bhattacharya, Michael W Epperly, et al.
Leukemia & Lymphoma|October 1, 2016
Ganetespib, an HSP90 inhibitor, kills Epstein-Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the bloodAmber Shatzer, Mir A Ali, Mayra Chavez, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Hormones & Cancer|February 10, 2016
Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast CancerAbena S Agyeman, Wesley J Jun, David A Proia, et al.
Targeted Oncology|August 1, 2014
The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancerDonald L Smith, Jaime Acquaviva, Manuel Sequeira, et al.
Molecular Cancer Therapeutics|September 27, 2012
Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespibJaime Acquaviva, Donald L Smith, Jim Sang, et al.
Molecular Cancer Therapeutics|January 9, 2014
Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespibJaime Acquaviva, Donald L Smith, John-Paul Jimenez, et al.
Oncotarget|September 10, 2016
STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcomaChristine M Heske, Arnulfo Mendoza, Leah D Edessa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2016
Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with ChemoradiationYifan Wang, Hui Liu, Lixia Diao, et al.
Plos One|December 5, 2014
Inhibiting heat shock protein 90 (HSP90) limits the formation of liver cysts induced by conditional deletion of Pkd1 in miceZachary B Smithline, Anna S Nikonova, Harvey H Hensley, et al.
Oncotarget|October 26, 2016
Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer modelsEgor Bobrov, Natalia Skobeleva, Diana Restifo, et al.
Cancers|May 27, 2015
The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma CellsRoberto Gomez-Casal, Chitralekha Bhattacharya, Michael W Epperly, et al.
Leukemia & Lymphoma|October 1, 2016
Ganetespib, an HSP90 inhibitor, kills Epstein-Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the bloodAmber Shatzer, Mir A Ali, Mayra Chavez, et al.
Pageof 5